CN102210724A - Comprehensive use of ovateleaf holly bark medicinal material - Google Patents
Comprehensive use of ovateleaf holly bark medicinal material Download PDFInfo
- Publication number
- CN102210724A CN102210724A CN 201110119062 CN201110119062A CN102210724A CN 102210724 A CN102210724 A CN 102210724A CN 201110119062 CN201110119062 CN 201110119062 CN 201110119062 A CN201110119062 A CN 201110119062A CN 102210724 A CN102210724 A CN 102210724A
- Authority
- CN
- China
- Prior art keywords
- cortex
- rotundae
- methanol
- ethanol
- pedunculoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000209035 Ilex Species 0.000 title abstract description 14
- 239000000463 material Substances 0.000 title abstract description 8
- 235000003332 Ilex aquifolium Nutrition 0.000 title abstract 13
- 235000002296 Ilex sandwicensis Nutrition 0.000 title abstract 13
- 235000002294 Ilex volkensiana Nutrition 0.000 title abstract 13
- 239000000284 extract Substances 0.000 claims abstract description 59
- LARPFJIXBULVPK-OIWQCSEESA-N Pedunculoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12[C@@H]([C@@](O)(C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)CC4)CC3)CC=1)CC2 LARPFJIXBULVPK-OIWQCSEESA-N 0.000 claims abstract description 52
- LARPFJIXBULVPK-FBAXZNBGSA-N [(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1r,2r,4as,6ar,6as,6br,8ar,9r,10s,12ar,14bs)-1,10-dihydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate Chemical compound O=C([C@]12CC[C@H]([C@@]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)CC[C@]4(C)[C@H]3CC=1)C)(C)CC2)(C)O)C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O LARPFJIXBULVPK-FBAXZNBGSA-N 0.000 claims abstract description 52
- LARPFJIXBULVPK-UHFFFAOYSA-N peduncloside Natural products C1CC(C2(CCC3C(C)(CO)C(O)CCC3(C)C2CC=2)C)(C)C=2C2C(O)(C)C(C)CCC21C(=O)OC1OC(CO)C(O)C(O)C1O LARPFJIXBULVPK-UHFFFAOYSA-N 0.000 claims abstract description 52
- QJVXKWHHAMZTBY-GCPOEHJPSA-N syringin Chemical compound COC1=CC(\C=C\CO)=CC(OC)=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 QJVXKWHHAMZTBY-GCPOEHJPSA-N 0.000 claims abstract description 47
- QJVXKWHHAMZTBY-KSXIZUIISA-N syringin Natural products COc1cc(C=CCO)cc(OC)c1O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O QJVXKWHHAMZTBY-KSXIZUIISA-N 0.000 claims abstract description 47
- 229930182490 saponin Natural products 0.000 claims abstract description 43
- 150000007949 saponins Chemical class 0.000 claims abstract description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 38
- 239000003814 drug Substances 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 23
- 239000002253 acid Substances 0.000 claims abstract description 22
- 208000031225 myocardial ischemia Diseases 0.000 claims abstract description 8
- 238000003809 water extraction Methods 0.000 claims abstract description 8
- 201000005577 familial hyperlipidemia Diseases 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 223
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 150
- 235000019441 ethanol Nutrition 0.000 claims description 104
- YLHQFGOOMKJFLP-LTFXOGOQSA-N Rotundic acid Chemical compound C1C[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@](O)(C)[C@H]5C4=CC[C@@H]3[C@]21C YLHQFGOOMKJFLP-LTFXOGOQSA-N 0.000 claims description 95
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 53
- YLHQFGOOMKJFLP-UHFFFAOYSA-N ilexolic acid A Natural products C1CC(O)C(C)(CO)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)C(O)(C)C5C4=CCC3C21C YLHQFGOOMKJFLP-UHFFFAOYSA-N 0.000 claims description 48
- 238000000605 extraction Methods 0.000 claims description 46
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 42
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 39
- 239000012043 crude product Substances 0.000 claims description 37
- 238000010992 reflux Methods 0.000 claims description 36
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 33
- 239000007788 liquid Substances 0.000 claims description 33
- 239000012567 medical material Substances 0.000 claims description 32
- 239000002904 solvent Substances 0.000 claims description 29
- 239000003960 organic solvent Substances 0.000 claims description 27
- 239000000741 silica gel Substances 0.000 claims description 27
- 229910002027 silica gel Inorganic materials 0.000 claims description 27
- 239000002244 precipitate Substances 0.000 claims description 17
- 238000001953 recrystallisation Methods 0.000 claims description 17
- 239000012046 mixed solvent Substances 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- 239000000377 silicon dioxide Substances 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- 239000006071 cream Substances 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 239000006286 aqueous extract Substances 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 8
- 239000003495 polar organic solvent Substances 0.000 claims description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 6
- 238000002481 ethanol extraction Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 4
- 238000007598 dipping method Methods 0.000 claims description 4
- 230000000146 antalgic effect Effects 0.000 claims description 3
- 238000005325 percolation Methods 0.000 claims description 3
- 239000003208 petroleum Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 238000000151 deposition Methods 0.000 claims description 2
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims description 2
- 235000021050 feed intake Nutrition 0.000 claims description 2
- 238000003808 methanol extraction Methods 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 235000017709 saponins Nutrition 0.000 abstract description 38
- 229940079593 drug Drugs 0.000 abstract description 5
- 206010002383 Angina Pectoris Diseases 0.000 abstract description 2
- 241000196324 Embryophyta Species 0.000 abstract description 2
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 208000002193 Pain Diseases 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 230000036407 pain Effects 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 239000002893 slag Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000010923 batch production Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 23
- 239000000706 filtrate Substances 0.000 description 17
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 238000010438 heat treatment Methods 0.000 description 13
- 238000001035 drying Methods 0.000 description 12
- 241000700159 Rattus Species 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 238000000638 solvent extraction Methods 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 description 8
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 8
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000002386 leaching Methods 0.000 description 7
- 210000003371 toe Anatomy 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 238000004811 liquid chromatography Methods 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 4
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 239000000469 ethanolic extract Substances 0.000 description 4
- 229930182478 glucoside Natural products 0.000 description 4
- 150000008131 glucosides Chemical class 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- 150000002338 glycosides Chemical class 0.000 description 4
- 239000013558 reference substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 230000001760 anti-analgesic effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- -1 filter Chemical compound 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000401 methanolic extract Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 208000005577 Gastroenteritis Diseases 0.000 description 2
- 235000008702 Ilex rotunda Nutrition 0.000 description 2
- 241000519740 Ilex rotunda Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229930182493 triterpene saponin Natural products 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000012873 acute gastroenteritis Diseases 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 102000011759 adducin Human genes 0.000 description 1
- 108010076723 adducin Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229960002662 propylthiouracil Drugs 0.000 description 1
- 108700022737 rat Fat1 Proteins 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- KCDXJAYRVLXPFO-UHFFFAOYSA-N syringaldehyde Chemical compound COC1=CC(C=O)=CC(OC)=C1O KCDXJAYRVLXPFO-UHFFFAOYSA-N 0.000 description 1
- YIBXWXOYFGZLRU-UHFFFAOYSA-N syringic aldehyde Natural products CC12CCC(C3(CCC(=O)C(C)(C)C3CC=3)C)C=3C1(C)CCC2C1COC(C)(C)C(O)C(O)C1 YIBXWXOYFGZLRU-UHFFFAOYSA-N 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000011003 system suitability test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses the comprehensive use of an ovateleaf holly bark medicinal material, which relates to method for extracting and separating from plants and use in field of medicines, in particular to a method for extracting syringin, pedunculoside, ovateleaf holly bark acid and ovateleaf holly bark total saponins from an ovateleaf holly bark medicinal material and use. In the invention, the syringing is prepared from water extract solution of the ovateleaf holly bark medicinal material, the pedunculoside and ovateleaf holly bark acid are prepared from medicine slag obtained after water extraction from the ovateleaf holly bark medicinal material, the purities of the syringin, pedunculoside and ovateleaf holly bark acid are all over 98 percent, and the ovateleaf holly bark total saponins are extracted from the medicine slag obtained after the water extraction from the ovateleaf holly bark medicinal material. The ovateleaf holly bark total saponins can be used for preparing medicines for preventing and treating hyperlipemia, medicines for relieving myocardial ischemia and angina and medicines for treating inflammation and pain. The invention has the advantages that: four active ingredients can be obtained from the ovateleaf holly bark medicinal material and resources can be fully utilized; and 2, the raw materials are readily available, the process is simple, the quality is controllable and batch production can be performed.
Description
Technical field
The present invention relates to derive from the field of medicaments extraction separation method and the application of plant, be specifically related to from the Cortex Ilicis Rotundae medical material, extract simultaneously the method and the application of syringoside, pedunculoside, rotundicacid and total saponin of Cortex Ilecis Rotundae.
Background technology
The Chinese crude drug Cortex Ilicis Rotundae is the dry bark of holly plant Ilex rotunda Thunb. (Ilex rotunda Thunb.), be distributed widely in the southern china each province, main product in Guangxi, Guangdong Province, the heat-clearing and toxic substances removing that is usually used among the people, reducing swelling and alleviating pain, heating cures cold, acute, chronic hepatitis, acute gastroenteritis, gastric and duodenal ulcers, rheumatic arthritis.The chemical constitution study report of Cortex Ilicis Rotundae is few, at document " Cortex Ilicis Rotundae The Chemical Constituents " Chinese herbal medicine, 1991,22 (6): reported among the 246-248 that containing rotundic acid in the Cortex Ilicis Rotundae is that rotundicacid, Peltatin glucoside are pedunculoside, rotundic acid isopropylidene ketal, syringoside, sinapyladehyde, sinapyladehyde glucoside, syringic aldehyde, 3 one acetyloleanolic acids and stearic acid.
Contain a large amount of pentacyclic triterpene saponins in the Cortex Ilicis Rotundae, according to document " content of Peltatin glucoside in the high effective liquid chromatography for measuring Cortex Ilicis Rotundae medical material " special product research 2007, the 4:45-47 report, the content of Peltatin glucoside is up to 8.8% in the Cortex Ilicis Rotundae medical material, if add the content of its aglycon rotundicacid, its total saponin content is higher.The Cortex Ilicis Rotundae medical material has now recorded 2010 editions one one of Chinese Pharmacopoeia, and in 293 pages, pharmacopeia stipulates that the content of its pedunculoside must not be lower than 4%, and syringoside content must not be lower than 1%.Medical material is mainly made the treatment gastroenteritis with its water extract at present, the Chinese patent medicine of diseases such as dyspepsia, as the Cortex Ilicis Rotundae tabellae contragasteralgiam, compound recipe Cortex Ilicis Rotundae capsule, fukean tablet, the suitable capsule of the intestines and stomach etc., extraction process all adopts water extraction method, Cortex Ilicis Rotundae medicinal residues after the extraction discard as waste residue, and neither environmental protection is again a kind of waste.We find Cortex Ilicis Rotundae medical material water extraction method, have mainly extracted the water soluble ingredient syringoside in the Cortex Ilicis Rotundae, do not extract fully and also have a lot of pentacyclic triterpene saponins in the medicinal residues, have caused the waste of resource.Main purpose of the present invention is to extract pedunculoside, rotundicacid and total saponin of Cortex Ilecis Rotundae the medicinal residues after Cortex Ilicis Rotundae water is carried, makes medicine, reduces production costs, and brings benefit to the mankind.
Cortex Ilicis Rotundae is the medical material that extensive use is arranged, at Chinese patent CN101032534A the preparation method of Cortex Ilicis Rotundae total glycosides is disclosed and in the application of diseases of cardiovascular and cerebrovascular systems, its extracting method is that the Cortex Ilicis Rotundae medical material is directly used ethanol extraction, the total saponin of Cortex Ilecis Rotundae of mentioning in the patent is actually a Cortex Ilicis Rotundae extract, because there is not chemical data to show that it is a saponin in the patent, composition in the total saponins, content all do not have and show that quality is restive.
Effective ingredient purposes in the Cortex Ilicis Rotundae has more report and patent, Chinese patent CN101342186A discloses pedunculoside (pedunculoside) and has been used for the treatment of hyperlipemia, CN101033245A also discloses pedunculoside and can be used for treating coronary heart disease, angina pectoris, apoplexy, the cerebral infarction diseases of cardiovascular and cerebrovascular systems of waiting indefinitely, CN101342186A discloses rotundicacid (Rotundic acid) and has been used for the treatment of hyperlipemia, Acta Pharmaceutica Sinica, 1980,15 (5): 303-305 has reported that syringoside has anastalsis, external medicine, the Chinese medicine fascicle, 2000,22 (6): 346-347 has reported that syringoside has hepatoprotective effect, document PlantaMed., 2004,70:1027-1032 has reported that again syringoside has anti-inflammatory and analgesic effect.
Summary of the invention
The objective of the invention is to, a kind of Cortex Ilicis Rotundae medical material comprehensive utilization method is provided.
For implementing the technical scheme that purpose of the present invention adopts is to make syringoside from the aqueous extract of Cortex Ilicis Rotundae medical material, makes rotundicacid and/or total saponin of Cortex Ilecis Rotundae from the medicinal residues behind the Cortex Ilicis Rotundae medical material water extraction,
The concrete operations step:
Concrete operations step: one, Cortex Ilicis Rotundae medical material water extraction, get aqueous extract 1 and medicinal residues 2 after the filtration, after aqueous extract 1 concentrates, alcohol deposition method precipitation with routine, filter alcohol deposit fluid 3, alcohol deposit fluid 3 reclaims ethanol, concentrate rare extractum 4, rare extractum 4 adds the silica gel mixing, the dry silica gel dried cream powder 5 that gets, the reuse organic solvent A is extracted, get organic solvent A extracting solution 6, extracting solution 6 reclaims solvent to doing, obtain syringoside extract 7, add the dissolving of organic solvent B reflux, filter, get organic solvent B liquid 8, place, filter, precipitate is a syringoside crude product 9, crude product 9 usefulness ethanol or recrystallizing methanol get purity at the syringoside more than 98% 10, said organic solvent A is an acetone or in the volume ratio chloroform: methanol or ethanol are 1: 0.02～0.1 or dichloromethane: methanol or ethanol are two kinds of mixed solvents of 1: 0.02～0.1, and said organic solvent B is in volume ratio ethanol or methanol: dichloromethane is 1: 0.2～3, ethanol or methanol: chloroform is two kinds of mixed solvents of 1: 0.2～3;
Two, with medicinal residues 2 usefulness ethanol or methanol extraction, filter alcohol extract 11, alcohol extract 11 reclaims solvent, be concentrated into extractum, add the silica gel mixing, dry, get alcohol extract silica white 12, alcohol extract silica white 12 usefulness weakly polar organic solvents extract, get Cortex Ilicis Rotundae acid extraction liquid 14 and residue 15, get extracting solution 14 and reclaim solvents, place, filter, get Cortex Ilicis Rotundae acid crude 16, rotundicacid crude product 16 usefulness methanol or ethyl alcohol recrystallization get purity at the rotundicacid more than 98% 17, and said weakly polar organic solvent is chloroform, benzene, dichloromethane or petroleum ether;
And/or alcohol extract 11 reclaimed be concentrated into feed intake 0.5～2 times of weight of Cortex Ilicis Rotundae behind the solvents, after the water that adds 2～5 times of concentrated solution weight again stirs evenly, filter, get precipitate 13, the dry total saponin of Cortex Ilecis Rotundae 21 that gets contains pedunculoside 50～80% and rotundicacid 5～30% in the total saponin of Cortex Ilecis Rotundae 21.
In order to utilize medical material better, can further the strong polar organic solvent of said residue 15 usefulness of second step be extracted, get pedunculoside extracting solution 18, reclaim solvent to doing, solids is a pedunculoside crude product 19, with volumetric concentration is that 30～100% methanol or 30～95% ethyl alcohol recrystallizations get purity at the pedunculoside more than 98% 20
Said strong polar organic solvent is ethyl acetate, ethanol, methanol.
Said alcohol extract 11 in the step 2 is the methanol of 70-100% or the ethanol extraction gained that volumetric concentration is 70-95% with volumetric concentration preferably, and extracting method can adopt conventional reflux extraction, percolation extraction method or dipping extraction method.
From the medicinal residues that Cortex Ilicis Rotundae water is carried, extract total saponin of Cortex Ilecis Rotundae 21, be used for preparation and prevent and treat hyperlipemia, improve myocardial ischemia, anginal Chinese medicine preparation, its toxicity is lower, and side effect is little, and has anti-inflammatory and analgesic effect, can be used for preparing the medicine of anti-inflammatory and antalgic, treat the medicine of rheumatic arthritis etc. as preparation.Required various conventional adjuvant when total saponin of Cortex Ilecis Rotundae 21 is added the preparation different dosage forms, process of Chinese medicine preparation is routinely made any oral formulations such as tablet, hard capsule, soft capsule, granule, oral liquid, syrup, drop pill or slow releasing tablet etc.
Beneficial effect of the present invention: 1, obtain four kinds of active component simultaneously, make full use of resource, reduce production costs from the Cortex Ilicis Rotundae medical material; 2, raw material is easy to get, and technology is simple, easy to operate, and product quality is easy to control, can put into production in enormous quantities; 3, total saponin of Cortex Ilecis Rotundae is effective blood fat reducing, improves myocardial ischemia and is used to prepare the medicine of anti-inflammatory and antalgic, and its toxicity is lower, and side effect is little.
Description of drawings
Fig. 1 is the process chart of Cortex Ilicis Rotundae medical material comprehensive utilization
Further set forth technical scheme of the present invention below in conjunction with drawings and Examples
The specific embodiment
Below set forth technical scheme of the present invention and beneficial effect by testing example
The preparation of test example 1 syringoside, total saponin of Cortex Ilecis Rotundae, pedunculoside and rotundicacid, as shown in Figure 1
The preparation of step 1 syringoside
Get Cortex Ilicis Rotundae medical material 10Kg, be ground into coarse powder, decoct secondary, add water 80Kg at every turn, each 2 hours, collecting decoction, get aqueous extract 1 and medicinal residues 2 after the filtration, medicinal residues 2 are standby, and aqueous extract 1 is concentrated into 4Kg, add the 12Kg ethanol precipitation, placed 24 hours, filter, get alcohol deposit fluid 3, be concentrated into rare extractum 4 adding silica gel 1.5Kg mixings after reclaiming ethanol, the dry silica gel dried cream powder 5 that gets places continuous circulation extraction separator, use chloroform: the methanol volume ratio is 1: 0.05 a mixed solvent 13000ml reflux, extract,, get organic solvent A extracting solution 6, reclaim solvent, obtain syringoside extract 7 to doing, reuse ethanol: chloroform volume ratio is 1: 0.5 mixed organic solvents 3500ml reflux dissolving, filter, get organic solvent B liquid 8, place, the leaching precipitate, drying is syringoside crude product 9, and crude product 9 usefulness ethyl alcohol recrystallizations must get syringoside 43.8g, measure with high-efficient liquid phase technique, see 2010 editions one one of Chinese Pharmacopoeia, 293 pages, purity is 98.68%.
The preparation of step 2 rotundicacid and total saponin of Cortex Ilecis Rotundae
Get above-mentioned Cortex Ilicis Rotundae medicinal residues 2, add 95% ethanol 30Kg at every turn, the reflux, extract, secondary, each 2 hours, merge secondary raffinate, filter, get alcohol extract 11 56Kg altogether, get half 28Kg (second half 28Kg is standby), reclaim ethanol and be concentrated into extractum, add silica gel 500g mixing, dry, get alcohol extract silica white 12, alcohol extract silica white 12 places continuous circulation extraction separator, extracts with chloroform 4000ml, get Cortex Ilicis Rotundae acid extraction liquid 14 and residue 15, get extracting solution 14 and reclaim chloroform, place, filter to 1500ml, precipitate is a rotundicacid crude product 16, rotundicacid crude product 16 usefulness ethyl alcohol recrystallizations get rotundicacid 34.5g, use high effective liquid chromatography for measuring, and content is 98.11%.
Get Cortex Ilicis Rotundae alcohol extract 11 second half amount 28Kg, reclaim ethanol, be concentrated into 5.0Kg, add water 15.0Kg, stir evenly, filter, get precipitate 13, the dry total saponin of Cortex Ilecis Rotundae 246g that gets, use high effective liquid chromatography for measuring, contain pedunculoside 61.81%, contain rotundicacid 22.66%.
The preparation of step 3 pedunculoside
Residue 15 in second step behind the chloroform extraction, reuse ethanol 3500ml reflux, extract, is to there not being pedunculoside, filter, pedunculoside extracting solution 18, reclaim ethanol and be concentrated into driedly, solids is a pedunculoside crude product 19, use 50% ethyl alcohol recrystallization, get pedunculoside 122g, use high effective liquid chromatography for measuring, content is 98.23%.
The high effective liquid chromatography for measuring pedunculoside, the method for rotundicacid and total saponin of Cortex Ilecis Rotundae content:
Chromatographic condition and system suitability test are filler with octadecylsilane chemically bonded silica; Acetonitrile: 0.1% phosphoric acid solution (50: 50) is made mobile phase; The detection wavelength is 210nm.
The pedunculoside reference substance is got in the preparation of reference substance solution respectively, the rotundicacid reference substance is an amount of, and accurate the title decides, and adds methanol and makes the solution that every 1ml contains pedunculoside 150 μ g, rotundicacid 50 μ g respectively, promptly.
Above-mentioned pedunculoside and rotundicacid are got in the preparation of need testing solution respectively, and porphyrize is respectively got about 0.02g, and accurate the title decides, put in the 100ml measuring bottle, it is an amount of to add methanol, and at power 250W, supersound process is 10 minutes under the frequency 50KHz, put coldly, add methanol and be diluted to scale, shake up, promptly.
Get above-mentioned total saponin of Cortex Ilecis Rotundae, porphyrize is got about 0.025g, accurate claims surely, puts in the 100ml measuring bottle, and it is an amount of to add methanol, and at power 250W, supersound process is 10 minutes under the frequency 50KHz, puts coldly, adds methanol and is diluted to scale, shakes up, promptly.
Accurate respectively reference substance solution and each the 20 μ l of need testing solution of drawing of algoscopy inject chromatograph of liquid, measure, promptly.
The blood fat reducing of test example 2 active component total saponin of Cortex Ilecis Rotundae of the present invention resists myocardial ischemia and anti-inflammatory and analgesic effect
1. the effect of the blood fat reducing of Cortex Ilicis Rotundae total glycosides
Get 50 of cleaning level SD rats, female, body weight 210 ± 10g is divided into 5 groups at random, 10 every group, press table 1 grouping, after each group freely absorb the normal diet adaptability and fed a week, except that the blank group, all the other were respectively organized and measure the filling stomach by 10ml/kg every day and give the fat milk of high fat (100ml contains 15g Adeps Sus domestica, the 6g cholesterol, the 2g cholate, 0.2g propylthiouracil and 20mL Tween 80,65mL distilled water), last till that experiment finishes, after one week of modeling, normal group and model group are given 1% sodium carboxymethyl cellulose (1ml/100g body weight), and all the other respectively organize gastric infusion, medicine all is mixed with 1% sodium carboxymethyl cellulose suspension (1ml/100g body weight), every day 1 time is according to table 1 grouping administration, successive administration 21 days, claimed 1 body weight in per three days, to adjust dosage.Each treated animal in administration after 21 days fasting can't help water 16h, pluck eyeball and get blood, separation of serum is measured serum total cholesterol (TC), serum triglycerides (TG), serum high-density LP cholesterol (HDL-C) and serum low-density LP cholesterol (LDL-C).The results are shown in Table 1
Table 1 total saponin of Cortex Ilecis Rotundae is to the influence of hyperlipidemia model rat fat index
Annotate: compare with model group, there were significant differences in * P＜0.05; There is highly significant difference * P＜0.01
Compare with normal group, there were significant differences in △ P＜0.05; There is highly significant difference △ △ P＜0.01
The result shows that to the rat of hyperlipemia, total saponin of Cortex Ilecis Rotundae can significantly reduce serum total cholesterol (TC) and serum triglycerides (TG) content; Significantly reduce serum low-density LP cholesterol level (LDL-C), serum high-density LP cholesterol (HDL-C) content significantly raises.
2. the Cortex Ilicis Rotundae total glycosides is to the Electrocardiographic influence of rat pituitary pituitrin disposition acute myocardial ischemia model
40 of the SD rats that the electrograph of coring screening is just being used always, male and female half and half, be divided into 4 groups at random, every group 10, press table 2 grouping, all medicine groups all are made into the suspension (1ml/100g body weight) of 1% sodium carboxymethyl cellulose, model control group is given 1% sodium carboxymethyl cellulose (1ml/100g body weight), each organizes gastric infusion 1 time every day, according to table 2 grouping administration, successive administration 5 days, after the last administration 1 hour, with 3% pentobarbital acid sodium (1ml/Kg) intraperitoneal injection of anesthesia, be fixed, connect electrocardiograph, intravenous injection pituitrin (0.5U/Kg) subsequently, injection finishes in 10 seconds, observes 10 minutes electrocardiogram of record, measures the ST section in back 30 seconds of the injection and the variation of T ripple.The results are shown in Table 2.
Table 2 total saponin of Cortex Ilecis Rotundae causes the influence of Acute Myocardial Ischemia in Rats to pituitrin
Annotate: compare * P＜0.05 with model control group; * P＜0.01
The result shows that total saponin of Cortex Ilecis Rotundae can resist obviously that pituitrin causes the animal acute myocardial ischemia and the electrocardiogram that takes place changes, and suppresses that the T wave height is alarmmed and the ST section is raised, and is remarkable with the model control group comparing difference.
3. the on Carrageenan of Cortex Ilicis Rotundae total glycosides causes the influence of rat toes swelling
40 of SD rats, male and female half and half, be divided into 4 groups at random, every group 10, press table 3 grouping, all medicine groups all are made into the suspension (1ml/100g body weight) of 1% sodium carboxymethyl cellulose, the blank group is given 1% sodium carboxymethyl cellulose (1ml/100g body weight), each organizes gastric infusion 1 time every day, according to table 3 grouping administration, successive administration 7 days.1h causes inflammation in the right back toes subcutaneous injection 1% carrageenin solution 0.1ml of every Mus after the last administration, with toes volume determination instrument measure respectively cause scorching before and cause scorching back 1,3,5,7h toes volume, with each Mus cause scorching before and after volumetrical difference be the swelling degree.Result such as table 3.
Table 3 total saponin of Cortex Ilecis Rotundae to the volumetrical influence of toes swelling rat toes (
N=10)
Annotate: compare * P＜0.05 with the blank group; * P＜0.01
The result shows, carrageenin causes scorching back 1h, and the rat toes begin variations such as the acute inflammation sample is red, swollen, and about 3h swelling reaches the peak.Total saponin of Cortex Ilecis Rotundae begins to produce curative effect in causing scorching back 1h, at 1h, 3h, the inductive rat paw edema of each time point on Carrageenan of 5h, 7h inhibitory action is significantly arranged all.
4. the total saponin of Cortex Ilecis Rotundae Dichlorodiphenyl Acetate causes the influence of mouse writhing reaction
40 of ICR mices, male and female half and half, be divided into 4 groups at random, every group 10, press table 3 grouping, all medicine groups all are made into the suspension (1ml/100g body weight) of 1% sodium carboxymethyl cellulose, the blank group is given 1% sodium carboxymethyl cellulose (1ml/100g body weight), and each organizes gastric infusion 1 time every day, according to table 4 grouping administration, successive administration 5 days, 0.5h after the last administration, every mouse peritoneal is injected 0.7% acetum 0.2ml, the writhing response that mice occurs in the counting 15min, comprise that stretching hind leg, abdominal part indent and buttocks raises number of times, calculates the analgesia rate.Result such as table 4.
The influence that table 4 Cortex Ilicis Rotundae extract reacts mouse writhing (
N=10)
Annotate: compare: * P＜0.05, material P＜0.01 with the blank group
The result shows that total saponin of Cortex Ilecis Rotundae can reduce the mouse writhing reaction times due to the acetic acid, has analgesic activity.
The acute toxicity test in mice of test example 3, total saponin of Cortex Ilecis Rotundae
Mouse stomach total saponin of Cortex Ilecis Rotundae 1.25,2.5,5,10g/kg do not see in two weeks that death and other abnormal response take place, and can't measure the LD50 that is subjected to reagent thing mouse stomach.Mice is with Cmax, maximum volume, and no overt toxicity reaction does not also have dead behind interior three gastric infusions of 24h in one week.The maximum dosage-feeding that records the administration of total saponin of Cortex Ilecis Rotundae mouse stomach is 60g/kg.
It is lower that more than the test poison that tentatively shows total saponin of Cortex Ilecis Rotundae is paid effect.
Further set forth technical scheme of the present invention below by embodiment and accompanying drawing
Syringoside, pedunculoside, rotundicacid preparation
Embodiment 1
Get Cortex Ilicis Rotundae medical material 1Kg, be ground into coarse powder, decoct with water secondary, each 2 hours, add water 10kg for the first time, add water 7Kg for the second time, collecting decoction filters, and medicinal residues 2 are standby, filtrate 1 is concentrated into 0.3Kg, add 0.6Kg ethanol, left standstill 24 hours, filter, filtrate is that alcohol deposit fluid 3 is concentrated into the rare extractum 4 of 200g, add 150g silica gel and disperse to stir evenly, dry that silica gel dried cream powder 5 places continuous circulation extraction separator, use dichloromethane: the ethanol volume ratio is 1: 0.1 a mixed solvent 1300ml reflux, extract,, effluent in separator has not had syringoside with the thin layer chromatography inspection, get organic solvent extraction liquid 6, reclaim solvent, obtain syringoside extract 7 to doing, reuse methanol: the methylene chloride volume ratio is 1: 3 mixed solvent 320ml reflux dissolving, filter, get organic solvent fluid 8, leave standstill, the leaching precipitate, be syringoside crude product 9, crude product 9 is used ethyl alcohol recrystallization, filters, dry syringoside 4.5g, the content 98.12% of getting.
Above-mentioned medicinal residues 2 are at every turn with 95% ethanol 3Kg reflux, extract, secondary, each 2 hours, merge extractive liquid,, filter, get ethanol extract 11, reclaim ethanol, be concentrated into extractum, add 100g silica gel mixing, drying gets alcohol extract silica white 12, be added in the continuous circulation extraction separator, elder generation to there not being rotundicacid, gets Cortex Ilicis Rotundae acid extraction liquid 14 and residue 15 with dichloromethane 1000ml heating and refluxing extraction, gets extracting solution 14 and reclaims solvents, be concentrated into 300ml, place, filter, get Cortex Ilicis Rotundae acid crude 16, the reuse ethyl alcohol recrystallization, filter, the dry rotundicacid 6.9g that gets, content reaches 98.58%;
Residue 15 in the extractor, reuse ethyl acetate 900ml heating and refluxing extraction is not to there being pedunculoside, and extracting solution 18 reclaims solvent, be concentrated into driedly, obtain pedunculoside crude product 19, crude product 19 50% ethyl alcohol recrystallization, filter, drying obtains pedunculoside 25.1g, and content reaches 98.72%.
Embodiment 2
Get Cortex Ilicis Rotundae medical material 1Kg, be ground into coarse powder, decoct with water secondary, each 2 hours, add for the first time water 8kg, for the second time add water 6Kg, collecting decoction filters, medicinal residues 2 are standby, filtrate 1 is concentrated into 0.4Kg, adds 1.6Kg ethanol, leaves standstill 24 hours, filter, filtrate 3 is concentrated into rare extractum 4 of 200g, adds 150g silica gel and disperses to stir evenly, and dried silica gel dried cream powder 5 places continuous circulation extraction separator, use dichloromethane: the methanol volume ratio is 1: 0.02 a mixed solvent 1200ml reflux, extract,, effluent in separator has not had syringoside with the thin layer chromatography inspection, organic solvent extraction liquid 6 reclaim solvents to do syringoside extract 7, reuse methanol: chloroform volume ratio is 1: 0.2 mixed solvent 250ml reflux dissolving, filter, get organic solvent fluid 8, leave standstill, the leaching precipitate is a syringoside crude product 9, crude product 9 is used recrystallizing methanol, filter dry syringoside 5.1g, the content 98.31% of getting.
Above-mentioned medicinal residues 2 usefulness methanol flood secondary, add methanol 6Kg, lixiviate 48 hours for the first time, add for the second time methanol 4Kg, lixiviate 24 hours, merge extractive liquid, again, filter, filtrate is methanol extract liquid 11, reclaims methanol, be concentrated into extractum, add 100g silica gel mixing, the dry alcohol extract silica white 12 that gets, place continuous circulation extraction separator, elder generation to there not being rotundicacid, gets Cortex Ilicis Rotundae acid extraction liquid 14 with chloroform 800ml heating and refluxing extraction, residue 15 is standby, rotundicacid extracting solution 14 reclaims solvent, is concentrated into 350ml, places, filter, get Cortex Ilicis Rotundae acid crude 16, the reuse ethyl alcohol recrystallization filters, the dry rotundicacid 6.5g that gets, content reaches 98.42%;
Residue 15 in the extractor, reuse ethanol 700ml heating and refluxing extraction is to there not being pedunculoside, pedunculoside extracting solution 18 reclaims solvent, be concentrated into the dried pedunculoside crude product 19 that obtains, crude product 19 60% recrystallizing methanol, filter, drying obtains pedunculoside 22.5g, and content reaches 98.55%;
Embodiment 3
Get Cortex Ilicis Rotundae medical material 1Kg, be ground into coarse powder, decoct with water secondary, each 2 hours, add water 8kg for the first time, add for the second time water 8Kg, collecting decoction filters, and medicinal residues 2 are standby, filtrate 1 is concentrated into 0.5Kg, add 1.5Kg ethanol, left standstill 24 hours, filter, filtrate 3 is concentrated into rare extractum 4 of 200g, add 150g silica gel and disperse to stir evenly, dried silica gel dried cream powder 5 places continuous circulation extraction separator, with acetone 1200ml reflux, extract,, effluent in separator has not had syringoside with the thin layer chromatography inspection, organic solvent extraction liquid 6 reclaim solvents to do syringoside extract 7, reuse ethanol: chloroform volume ratio is 1: 3 mixed solvent 300ml reflux dissolving, filters, filtrate 8 is left standstill, the leaching precipitate is a syringoside crude product 9, and crude product 9 is used recrystallizing methanol, filters, dry syringoside 4.1g, the content 9880% of getting.
Above-mentioned medicinal residues 2 usefulness 70% alcohol reflux secondary adds 70% ethanol 5Kg for the first time, refluxes 4 hours, for the second time add 70% ethanol 4Kg again, refluxed merge extractive liquid, 3 hours, filter, get ethanol extract 11 and reclaim ethanol, be concentrated into extractum, add 100g silica gel mixing, the dry alcohol extract silica white 12 that gets places continuous circulation extraction separator, earlier with benzene 900ml heating and refluxing extraction to there not being rotundicacid, get Cortex Ilicis Rotundae acid extraction liquid 14, residue 15 is standby, and rotundicacid extracting solution 14 reclaims solvents, be concentrated into 350ml, place, filter, get Cortex Ilicis Rotundae acid crude 16, the reuse recrystallizing methanol, filter, the dry rotundicacid 4.2g that gets, content reaches 98.63%;
Residue 15 in the extractor, reuse methanol 800ml heating and refluxing extraction is not to there being pedunculoside, and organic solvent extraction liquid 18 reclaims solvent, be concentrated into driedly, obtain pedunculoside crude product 19, crude product 19 is used recrystallizing methanol, filter, drying obtains pedunculoside 24.3g, and content reaches 98.21%.
Embodiment 4
Get Cortex Ilicis Rotundae medical material 1Kg, be ground into coarse powder, decoct with water secondary, each 2 hours, add water 9kg for the first time, add for the second time water 5Kg, collecting decoction filters, and medicinal residues 2 are standby, filtrate 1 is concentrated into 0.4Kg, add 0.8Kg ethanol, left standstill 24 hours, filter, filtrate 3 is concentrated into rare extractum 4 of 200g, add 150g silica gel and disperse to stir evenly, dried silica gel dried cream powder 5 places continuous circulation extraction separator, uses chloroform: the methanol volume ratio is 1: 0.1 a mixed solvent 1300ml reflux, extract,, effluent in separator has not had syringoside with the thin layer chromatography inspection, organic solvent extraction liquid 6 reclaim solvents to do syringoside extract 7, reuse ethanol: chloroform volume ratio is 1: 2 mixed solvent 320ml reflux dissolving, filters, filtrate 8 is left standstill, the leaching precipitate is a syringoside crude product 9, and crude product 9 is used recrystallizing methanol, filters, dry syringoside 4.9g, the content 98.17% of getting.
Above-mentioned medicinal residues 2, add 85% ethanol percolate extraction, carry out percolation by 11 pages of methods of Pharmacopoeia of People's Republic of China appendix of version in 2005, not obvious to the liebermann-Burchard test until percolate, percolate 11 reclaims ethanol, be concentrated into extractum, add 100g silica gel mixing, the dry alcohol extract silica white 12 that gets places continuous circulation extraction separator, earlier with petroleum ether 1200ml heating and refluxing extraction to there not being rotundicacid, get Cortex Ilicis Rotundae acid extraction liquid 14, residue 15 is standby, and rotundicacid extracting solution 14 reclaims solvents, be concentrated into 380ml, place, filter, get Cortex Ilicis Rotundae acid crude 16, the reuse ethyl alcohol recrystallization gets rotundicacid 5.2g, and content reaches 98.25%;
Residue 15 in the extractor, reuse ethanol 650ml heating and refluxing extraction is not to there being pedunculoside, and organic solvent extraction liquid 18 reclaims solvent, be concentrated into the dried pedunculoside crude product 19 that obtains, crude product 19 30% ethyl alcohol recrystallization filters, drying obtains Folium Ilicis macrocarpae 29.8g, and content reaches 98.13%
Embodiment 5
Get Cortex Ilicis Rotundae medical material 1Kg, be ground into coarse powder, decoct with water secondary, each 2 hours, add water 8kg for the first time, add for the second time water 7Kg, collecting decoction filters, and medicinal residues 2 are standby, filtrate 1 is concentrated into 0.4Kg, add 1.2Kg ethanol, left standstill 24 hours, filter, filtrate 3 is concentrated into rare extractum 4 of 200g, add 150g silica gel and disperse to stir evenly, dried silica gel dried cream powder 5 places continuous circulation extraction separator, uses chloroform: the methanol volume ratio is 1: 0.05 a mixed solvent 1300ml reflux, extract,, effluent in separator has not had syringoside with the thin layer chromatography inspection, organic solvent extraction liquid 6 reclaims solvent and is syringoside extract 7, reuse ethanol to doing: chloroform volume ratio is 1: 1 mixed solvent 310ml reflux dissolving, filters, filtrate 8 is left standstill, the leaching precipitate is a syringoside crude product 9, and crude product 9 is used ethyl alcohol recrystallization, filters, dry syringoside 4.3g, the content 98.41% of getting.
Above-mentioned medicinal residues 2 usefulness 70% methanol eddy extracts secondary, adds 70% ethanol 5Kg for the first time, refluxes 4 hours, for the second time add 70% ethanol 4Kg again, refluxed merge extractive liquid, 3 hours, filter, alcohol extract 11 reclaims ethanol, is concentrated into extractum, add 100g silica gel mixing, the dry alcohol extract silica white 12 that gets places continuous circulation extraction separator, earlier with chloroform 800ml heating and refluxing extraction to there not being rotundicacid, get Cortex Ilicis Rotundae acid extraction liquid 14, residue 15 is standby, and rotundicacid extracting solution 14 reclaims solvents, be concentrated into 250ml, place, filter, get Cortex Ilicis Rotundae acid crude 16, the reuse recrystallizing methanol, filter, the dry rotundicacid 4.1g that gets, content reaches 98.51%;
Residue 15 in the extractor, reuse ethyl acetate 700ml heating and refluxing extraction is to there not being pedunculoside, organic solvent extraction liquid 18 reclaims solvent, be concentrated into dried, obtain pedunculoside crude product 19, crude product 19 30% recrystallizing methanol filters, drying obtains pedunculoside 24.8g, and content reaches 98.19%
Embodiment 6
Get Cortex Ilicis Rotundae medical material 1Kg, be ground into coarse powder, decoct with water secondary, each 2 hours, add water 8kg for the first time, add for the second time water 6Kg, collecting decoction filters, and medicinal residues 2 are standby, filtrate 1 is concentrated into 0.4Kg, add 1.6Kg ethanol, left standstill 24 hours, filter, filtrate 3 is concentrated into rare extractum 4 of 200g, add 150g silica gel and disperse to stir evenly, dry back silica gel dried cream powder 5 places continuous circulation extraction separator, and use chloroform: the ethanol volume ratio is 1: 0.02 a mixed solvent 1200ml reflux, extract,, effluent in separator has not had syringoside with the thin layer chromatography inspection, organic solvent extraction liquid 6 reclaims solvent and is syringoside extract 7, reuse ethanol to doing: the methylene chloride volume ratio is 1: 0.2 mixed solvent 280ml reflux dissolving, filters, filtrate 8 is left standstill, the leaching precipitate is a syringoside crude product 9, and crude product 9 is used ethyl alcohol recrystallization, filters, dry syringoside 4.2g, the content 98.32% of getting.
Above-mentioned medicinal residues 2 add 85% methanol eddy and extract secondary, add 85% methanol 5Kg for the first time, refluxed 2 hours, and added 85% methanol 4Kg more for the second time, refluxed 2 hours, merge extractive liquid, filters, and gets alcohol extract 9Kg, get the alcohol extract of 7.2Kg, be equivalent to primary dose 800g, (remaining alcohol extract 1.8Kg is standby) reclaims methanol, be concentrated into extractum, add 80g silica gel mixing, the dry alcohol extract silica white 12 that gets places continuous circulation extraction separator, earlier with chloroform 700ml heating and refluxing extraction to there not being rotundicacid, get Cortex Ilicis Rotundae acid extraction liquid 14, residue 15 is standby, and rotundicacid extracting solution 14 reclaims solvents, be concentrated into 200ml, place, filter, get Cortex Ilicis Rotundae acid crude 16, the reuse ethyl alcohol recrystallization, filter, the dry rotundicacid 4.3g that gets, content reaches 98.45%;
Residue 15 in the extractor, reuse ethyl acetate 750ml heating and refluxing extraction is to there not being pedunculoside, organic solvent extraction liquid 18 reclaims solvent, be concentrated into dried, obtain pedunculoside crude product 19, crude product 19 95% ethyl alcohol recrystallization filters, drying obtains pedunculoside 23.5g, and content reaches 98.33%
The total saponin of Cortex Ilecis Rotundae preparation
Embodiment 7
Get the 1.8Kg85% methanol extract liquid 11 of the foregoing description 6 remainders, reclaim methanol to 100g, add water 200g, stir evenly, filter, get precipitate 13, drying gets total saponin of Cortex Ilecis Rotundae 10.7g, includes pedunculoside 70.25%, rotundicacid 13.33%.
Embodiment 8
Get Cortex Ilicis Rotundae medical material 200g, press the water extracting method of embodiment 1,95% ethanol extraction of the medicinal residues after the filtration, get ethanol extract 11, reclaim ethanol to 400g, add water 2000g, stir evenly, filter, get precipitate 13, drying gets total saponin of Cortex Ilecis Rotundae 8.8g, include pedunculoside 51.38%, rotundicacid 28.86%.
Embodiment 9
Get Cortex Ilicis Rotundae medical material 200g, press the water extracting method of embodiment 2, the medicinal residues after the filtration extract with the methanol dipping, get methanol extract liquid 11, reclaim methanol to 300g, add water 900g, stir evenly, filter, get precipitate 13, drying gets total saponin of Cortex Ilecis Rotundae 10.9g, include pedunculoside 60.28%, rotundicacid 20.35%.
Embodiment 10
Get Cortex Ilicis Rotundae medical material 200g, press the water extracting method of embodiment 3, the medicinal residues after the filtration are with 70% alcohol dipping secondary, for the first time add 70% ethanol 600g, lixiviate 48 hours adds 70% ethanol 600g for the second time again, lixiviate 24 hours, merge extractive liquid, filters, ethanol extract 11 reclaims ethanol to 400g, adds water 800g, stirs evenly, filter, get precipitate 13, drying, get total saponin of Cortex Ilecis Rotundae 10.5g, include pedunculoside 78.28%, rotundicacid 5.54%.
Claims (5)
1. Cortex Ilicis Rotundae medical material comprehensive utilization method is characterized in that: from the aqueous extract of Cortex Ilicis Rotundae medical material, makes syringoside, from the medicinal residues behind the Cortex Ilicis Rotundae medical material water extraction, makes rotundicacid and/or total saponin of Cortex Ilecis Rotundae,
Concrete operations step: one, Cortex Ilicis Rotundae medical material water extraction, get aqueous extract (1) and medicinal residues (2) after the filtration, after aqueous extract (1) concentrates, alcohol deposition method precipitation with routine, filter alcohol deposit fluid (3), alcohol deposit fluid (3) reclaims ethanol, concentrate rare extractum (4), rare extractum (4) adds the silica gel mixing, the dry silica gel dried cream powder (5) that gets, the reuse organic solvent A is extracted, get organic solvent A extracting solution (6), extracting solution (6) reclaims solvent to doing, obtain syringoside extract (7), add the dissolving of organic solvent B reflux, filter, get organic solvent B liquid (8), place, filter, precipitate is syringoside crude product (9), crude product (9) gets purity in the syringoside more than 98% (10) with ethanol or recrystallizing methanol, said organic solvent A is an acetone or in the volume ratio chloroform: methanol or ethanol are 1: 0.02～0.1 or dichloromethane: methanol or ethanol are two kinds of mixed solvents of 1: 0.02～0.1, and said organic solvent B is in volume ratio ethanol or methanol: dichloromethane is 1: 0.2～3, ethanol or methanol: chloroform is two kinds of mixed solvents of 1: 0.2～3;
Two, with medicinal residues (2) with ethanol or methanol extraction, filter alcohol extract (11), alcohol extract (11) reclaims solvent, be concentrated into extractum, add the silica gel mixing, dry, get alcohol extract silica white (12), alcohol extract silica white (12) extracts with weakly polar organic solvent, get Cortex Ilicis Rotundae acid extraction liquid (14) and residue (15), get extracting solution (14) and reclaim solvent, place, filter, get Cortex Ilicis Rotundae acid crude (16), rotundicacid crude product (16) gets purity in the rotundicacid more than 98% (17) with methanol or ethyl alcohol recrystallization, and said weakly polar organic solvent is a chloroform, benzene, dichloromethane or petroleum ether;
And/or alcohol extract (11) reclaimed be concentrated into feed intake 0.5～2 times of weight of Cortex Ilicis Rotundae behind the solvent, after the water that adds 2～5 times of concentrated solution weight again stirs evenly, filter, get precipitate (13), the dry total saponin of Cortex Ilecis Rotundae (21) that gets contains pedunculoside 50～80% and rotundicacid 5～30% in the total saponin of Cortex Ilecis Rotundae (21).
2. according to the said Cortex Ilicis Rotundae medical material of claim 1 comprehensive utilization method, it is characterized in that: the said residue of second step (15) extracts with strong polar organic solvent, get pedunculoside extracting solution (18), reclaim solvent to doing, solids is pedunculoside crude product (19), with volumetric concentration is that 30～100% methanol or 30～95% ethyl alcohol recrystallizations get purity in the pedunculoside more than 98% (20)
Said strong polar organic solvent is ethyl acetate, ethanol, methanol.
3. according to the said Cortex Ilicis Rotundae medical material of claim 1 comprehensive utilization method, it is characterized in that: said alcohol extract (11) in the step 2, be to be that 70～100% methanol or volumetric concentration are 70～95% ethanol extraction gained with volumetric concentration, extracting method adopts conventional reflux extraction, percolation extraction method or dipping extraction method.
4. one kind is extracted total saponin of Cortex Ilecis Rotundae as claim 1 is said from the medicinal residues that Cortex Ilicis Rotundae water is carried, and is used for preparation and prevents and treats hyperlipemia, improves myocardial ischemia, anginal Chinese medicine preparation.
5. one kind is extracted total saponin of Cortex Ilecis Rotundae as claim 1 is said from the medicinal residues that Cortex Ilicis Rotundae water is carried, and is used to prepare the medicine of anti-inflammatory and antalgic.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101190620A CN102210724B (en) | 2011-05-09 | 2011-05-09 | Comprehensive utilization of ovate leaf holly bark medicinal material |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101190620A CN102210724B (en) | 2011-05-09 | 2011-05-09 | Comprehensive utilization of ovate leaf holly bark medicinal material |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102210724A true CN102210724A (en) | 2011-10-12 |
| CN102210724B CN102210724B (en) | 2012-11-14 |
Family
ID=44742409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101190620A Active CN102210724B (en) | 2011-05-09 | 2011-05-09 | Comprehensive utilization of ovate leaf holly bark medicinal material |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102210724B (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102342945A (en) * | 2011-07-26 | 2012-02-08 | 安士制药（中山）有限公司 | Application of Cortex Ilicis Rotundae saponin compound in preparing anti-inflammatory and analgetic medicament |
| CN102643322A (en) * | 2012-03-29 | 2012-08-22 | 中国中医科学院中药研究所 | Method for simultaneously preparing pedunculoside and syringin |
| CN103351419A (en) * | 2013-07-09 | 2013-10-16 | 陕西中药研究所 | Two-step simultaneous preparation method for pedunculoside and syringin |
| CN105646638A (en) * | 2016-01-20 | 2016-06-08 | 中山大学 | Preparation method of pedunculoside |
| CN108379307A (en) * | 2018-03-23 | 2018-08-10 | 广西中医药大学 | Cortex Ilicis Rotundae extract and its preparation and the application for treating gastroenteritis |
| CN109432147A (en) * | 2018-12-07 | 2019-03-08 | 青岛蔚蓝生物股份有限公司 | A kind of injection stage Cortex Ilicis Rotundae extract and preparation method thereof, compound iron holly bark injection and its preparation method and application |
| CN109970838A (en) * | 2019-03-19 | 2019-07-05 | 中山大学 | A kind of preparation method of pedunculoside |
| CN114644675A (en) * | 2020-12-21 | 2022-06-21 | 广西大学 | Method for separating compass herb glycoside B from ovate leaf holly bark |
| CN116003506A (en) * | 2022-12-30 | 2023-04-25 | 陕西嘉禾生物科技股份有限公司 | Method suitable for industrial production of pedunculoside and syringin |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101032534A (en) * | 2006-09-19 | 2007-09-12 | 李超生 | Method of preparing jiubiying total saponins and the application thereof |
| CN101099753A (en) * | 2006-07-07 | 2008-01-09 | 李超生 | Preparation method and application for general saponin of cortex ilecis rotundae |
| CN101342205A (en) * | 2008-09-01 | 2009-01-14 | 刘国樵 | Traditional Chinese medicine preparation for decreasing blood fat |
-
2011
- 2011-05-09 CN CN2011101190620A patent/CN102210724B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101099753A (en) * | 2006-07-07 | 2008-01-09 | 李超生 | Preparation method and application for general saponin of cortex ilecis rotundae |
| CN101032534A (en) * | 2006-09-19 | 2007-09-12 | 李超生 | Method of preparing jiubiying total saponins and the application thereof |
| CN101342205A (en) * | 2008-09-01 | 2009-01-14 | 刘国樵 | Traditional Chinese medicine preparation for decreasing blood fat |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102342945A (en) * | 2011-07-26 | 2012-02-08 | 安士制药（中山）有限公司 | Application of Cortex Ilicis Rotundae saponin compound in preparing anti-inflammatory and analgetic medicament |
| CN102643322A (en) * | 2012-03-29 | 2012-08-22 | 中国中医科学院中药研究所 | Method for simultaneously preparing pedunculoside and syringin |
| CN102643322B (en) * | 2012-03-29 | 2014-03-19 | 中国中医科学院中药研究所 | Method for simultaneously preparing pedunculoside and syringin |
| CN103351419A (en) * | 2013-07-09 | 2013-10-16 | 陕西中药研究所 | Two-step simultaneous preparation method for pedunculoside and syringin |
| CN103351419B (en) * | 2013-07-09 | 2015-10-07 | 陕西中药研究所 | Two-step approach prepares the method for pedunculoside and Syringin simultaneously |
| CN105646638A (en) * | 2016-01-20 | 2016-06-08 | 中山大学 | Preparation method of pedunculoside |
| CN108379307A (en) * | 2018-03-23 | 2018-08-10 | 广西中医药大学 | Cortex Ilicis Rotundae extract and its preparation and the application for treating gastroenteritis |
| CN109432147A (en) * | 2018-12-07 | 2019-03-08 | 青岛蔚蓝生物股份有限公司 | A kind of injection stage Cortex Ilicis Rotundae extract and preparation method thereof, compound iron holly bark injection and its preparation method and application |
| CN109970838A (en) * | 2019-03-19 | 2019-07-05 | 中山大学 | A kind of preparation method of pedunculoside |
| CN109970838B (en) * | 2019-03-19 | 2021-06-15 | 中山大学 | Preparation method of pedunculoside |
| CN114644675A (en) * | 2020-12-21 | 2022-06-21 | 广西大学 | Method for separating compass herb glycoside B from ovate leaf holly bark |
| CN114644675B (en) * | 2020-12-21 | 2023-05-16 | 广西大学 | Method for separating Luo Pancao glycoside B from holly bark |
| CN116003506A (en) * | 2022-12-30 | 2023-04-25 | 陕西嘉禾生物科技股份有限公司 | Method suitable for industrial production of pedunculoside and syringin |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102210724B (en) | 2012-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102210724B (en) | Comprehensive utilization of ovate leaf holly bark medicinal material | |
| CN102138966A (en) | Tibetan capillaris extract and preparation method, pharmaceutical composition and use thereof | |
| CN101342205B (en) | Traditional Chinese medicine preparation for decreasing blood fat | |
| CN101810715B (en) | New application of fructus evodiae and extracts and compounds thereof | |
| CN102512482A (en) | Euonymus alatus extract, blood-sugar-reducing activity thereof and application of euonymus alatus extract to preparation of products for reducing blood sugar | |
| CN101317883B (en) | Prunella spike active site and application of the same in preparing medicament composition | |
| WO2013155995A1 (en) | Red yeast and kudzu root pharmaceutical composition for regulating blood lipids and preparation method therefor | |
| CN102342945B (en) | Application of Cortex Ilicis Rotundae saponin compound in preparing anti-inflammatory and analgetic medicament | |
| CN101849950A (en) | Application of rotundic acid in preparing blood lipid regulating medicines | |
| CN104387362B (en) | A kind of iridoidate compound, its preparation method and application | |
| CN106349304A (en) | Method for preparing high-purity Urticaside and Urticalignans | |
| CN1887837A (en) | Extraction process and application of emodin and aloe-emodin | |
| CN101342186B (en) | Use of pentacyclic triterpene saponin compound | |
| CN100477996C (en) | Extract of star of bethlehem and its prepn process, medicinal composition and use | |
| CN104804056A (en) | Sarcopyramis nepalensis extract and application thereof | |
| CN109674848A (en) | A kind of preparation method and purposes of licorice | |
| CN1312170C (en) | Technique of preparing extract product of Radde Anemone Rhizome extract, and its application in preparing medication of treating cancer | |
| CN107266464B (en) | A kind of rhizoma alismatis decoction extract and its application | |
| CN106822071B (en) | Chinese medicinal effective component for treating coronary heart disease and hyperlipidemia, its preparation method and method for separating effective component from the same | |
| CN100411653C (en) | Chinese medicine composition for treating diabetes mellitus | |
| CN101670007B (en) | Drug for preventing and treating kidney diseases and preparation method thereof | |
| CN101167824B (en) | Medicine for treating liver damage and its preparing process | |
| WO2013155997A1 (en) | Blood lipid-regulating red yeast ligusticum chuanxiong pharmaceutical composition and preparation method therefor | |
| CN113876826B (en) | Brachypodium delavayi extract and preparation method and application thereof | |
| CN101134070A (en) | Hepatitis treating medicine and method for preparing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: A + Z PHARMACEUTICAL ZHONGSHAN INC. Free format text: FORMER OWNER: LIU GUOQIAO Effective date: 20111028 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Xu Qingbo Inventor after: Liu Guoqiao Inventor after: Xu Xiaoxian Inventor after: Wang Wuping Inventor after: Li Jiawei Inventor before: Liu Guoqiao |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 510280 GUANGZHOU, GUANGDONG PROVINCE TO: ZHONGSHAN, GUANGDONG PROVINCE Free format text: CORRECT: INVENTOR; FROM: LIU GUOQIAO TO: XU QINGBO LIU GUOQIAO XU XIAOXIAN WANG WUPING LI JIAWEI |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20111028 Address after: Zhongshan National Health Science and technology industry base of Guangdong Province Applicant after: Anshi Pharmaceutical (Zhongshan) Inc. Address before: 1106, room 18, 510280 South Road, Yan Yan Street, Haizhuqu District, Guangdong, Guangzhou Applicant before: Liu Guoqiao |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |